What is the recommended adult dose and duration of treatment with Miralax (polyethylene glycol 3350) for constipation?

Recommended Adult Dose and Duration of Miralax for Constipation

For adults with constipation, use Miralax (polyethylene glycol 3350) 17 grams once daily mixed in 8 ounces of liquid, and continue treatment for at least 6 months as the response has been shown to be durable over this period. 1

Dosing Specifics

Standard Dose:

• 17 grams once daily is the FDA-approved and guideline-recommended dose 1
• Mix in 8 ounces (approximately 240 mL) of any beverage 1, 2
• Take as a single daily dose

Alternative Dosing (from clinical trials):

• Some studies used 17.5 grams twice daily (PEG with electrolytes), but the once-daily 17-gram dose without electrolytes is the standard FDA-approved regimen 1

Duration of Treatment

The 2023 AGA-ACG guidelines provide a strong recommendation for PEG use with moderate certainty evidence, noting that response is durable over 6 months 1. The evidence supporting this includes:

• 6-month efficacy demonstrated: The largest randomized controlled trial (304 patients) showed sustained efficacy over 6 months with 52% treatment success versus 11% with placebo 1, 3
• 12-month safety data available: An open-label study of 311 patients demonstrated continued safety and efficacy up to 12 months without tachyphylaxis 4
• Long-term use is appropriate: While FDA-approved for "occasional constipation," clinical evidence supports chronic use for chronic idiopathic constipation 1

Treatment Algorithm

Step 1: Initial Trial

• Start 17 grams once daily
• For mild constipation, consider fiber supplementation first or in combination with PEG 1

Step 2: Assess Response

• Evaluate after 2 weeks (peak efficacy typically seen in week 2) 5
• Success defined as ≥3 complete spontaneous bowel movements per week with improvement in straining, stool consistency, and global relief 1, 6

Step 3: Continue Long-term

• If effective, continue for at least 6 months 1
• No dose adjustment needed over time; no evidence of tolerance 4
• No clear maximum dose, but titrate based on response and side effects 1

Expected Outcomes

Based on the highest quality evidence 1, 6:

• Increased bowel movements: Mean increase of 2.3 spontaneous bowel movements per week
• Improved stool consistency: Reduction of 2.1 hard/lumpy stools per week
• High response rate: 42% met FDA responder definition (≥3 complete spontaneous bowel movements/week with ≥1 increase from baseline for ≥9/12 weeks)

Safety Considerations

Common Side Effects (generally mild to moderate) 1:

• Abdominal distension
• Loose stools/diarrhea (most common in first week, then decreases markedly)
• Flatulence
• Nausea

Important Safety Points:

• No clinically significant electrolyte disturbances even with 12-month use 4
• No serious adverse events identified in controlled trials 1
• Safe in elderly patients (similar efficacy and safety profile) 4, 3
• Widely available over-the-counter and relatively inexpensive ($10-45/month) 1

Clinical Pitfalls to Avoid

1. Don't limit to short-term use: Although FDA-approved for "occasional constipation," evidence supports chronic use for chronic idiopathic constipation 1

2. Don't underdose: The 17-gram daily dose is evidence-based; lower doses may be less effective

3. Don't discontinue prematurely: Response is durable over 6 months, and early discontinuation often leads to relapse 1

4. Don't worry about tachyphylaxis: No evidence of tolerance development even after 12 months of continuous use 4

5. Ensure adequate fluid intake: Mix with at least 8 ounces of liquid; patients with low baseline fluid intake should increase hydration 1